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Abstract
Background: The complement component C3a activates human mast cells via its cell surface G protein coupled receptor
(GPCR) C3aR. For most GPCRs, agonist-induced receptor phosphorylation leads to receptor desensitization, internalization
as well as activation of downstream signaling pathways such as ERK1/2 phosphorylation. Previous studies in transfected
COS cells overexpressing G protein coupled receptor kinases (GRKs) demonstrated that GRK2, GRK3, GRK5 and GRK6
participate in agonist-induced C3aR phosphorylation. However, the roles of these GRKs on the regulation of C3aR signaling
and mediator release in human mast cells remain unknown.
Methodology/Principal Findings: We utilized lentivirus short hairpin (sh)RNA to stably knockdown the expression of GRK2,
GRK3, GRK5 and GRK6 in human mast cell lines, HMC-1 and LAD2, that endogenously express C3aR. Silencing GRK2 or GRK3
expression caused a more sustained Ca
2+ mobilization, attenuated C3aR desensitization, and enhanced degranulation as
well as ERK1/2 phosphorylation when compared to shRNA control cells. By contrast, GRK5 or GRK6 knockdown had no
effect on C3aR desensitization, but caused a significant decrease in C3a-induced mast cell degranulation. Interestingly, GRK5
or GRK6 knockdown rendered mast cells more responsive to C3a for ERK1/2 phosphorylation.
Conclusion/Significance: This study demonstrates that GRK2 and GRK3 are involved in C3aR desensitization. Furthermore, it
reveals the novel finding that GRK5 and GRK6 promote C3a-induced mast cell degranulation but inhibit ERK1/2
phosphorylation via C3aR desensitization-independent mechanisms. These findings thus reveal a new level of complexity
for C3aR regulation by GRKs in human mast cells.
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Introduction
The complement component C3a plays an important role in
innate immunity and also promotes allergic diseases such as
bronchial asthma [1,2,3]. G protein coupled receptors for C3a
(C3aR) are expressed in human mast cell lines (HMC-1, LAD2),
differentiated CD34
+-derived primary human mast cells as well as
skin mast cells [4,5,6]. C3a induces Ca
2+ mobilization, causes
substantial degranulation and chemokine generation in human
mast cells via the activation of Gi-family of G proteins. Removal of
potential phosphorylation sites within the carboxyl terminus of
C3aR leads to more robust degranulation when compared to wild-
type receptors [7]. These findings are consistent with the idea that,
as in many other cell types, receptor phosphorylation desensitizes
C3aR expressed in mast cells [8].
Agonist occupied GPCRs are phosphorylated by a family of
protein kinases, collectively known as G protein coupled receptor
kinases (GRKs). Of the seven known GRKs, four (GRK2, GRK3,
GRK5 and GRK6) are expressed ubiquitously. It is well
established that GPCR phosphorylation by GRKs leads to the
recruitment of b-arrestin, which results in receptor desensitization
and internalization [8,9]. However, the role of specific GRKs on
receptor regulation has only been appreciated recently. Studies
with siRNA-mediated knockdown of GRKs in HEK293 cells have
shown that agonist-induced phosphorylation of angiotensin II type
1A receptor (Gq-coupled) and V2 vasopressin receptors (Gs-
coupled) are predominantly mediated by GRK2 and GRK3
[10,11]. Furthermore, knockdown of these GRKs attenuated both
agonist-induced b-arrestin recruitment and receptor desensitiza-
tion [10,11].
In addition to desensitization, receptor phosphorylation by
GRKs leads to the activation of extracellular signal-regulated
kinases (ERK1/2) in a b-arrestin-dependent manner. In HEK293
cells, knockdown of GRK5 and GRK6 inhibits angiotensin II and
vasopressin-induced b-arrestin-dependent ERK1/2 phosphoryla-
tion [12,13]. These findings suggest that for angiotensin type IA
and vasopressin receptors, agonist-induced receptor phosphoryla-
tion by GRK2/GRK3 leads to receptor desensitization but their
phosphorylation by GRK5/GRK6 promotes b-arrestin-depen-
dent ERK1/2 phosphorylation. However, for the chemokine
receptor CXCR4, GRK2/GRK6 are involved in receptor
desensitization whereas GRK3/GRK6 play an important role in
positively regulating ERK1/2 activation [14]. In transfected COS
cells, overexpression of GRK2, GRK3, GRK5 or GRK6 results in
enhancement of agonist-induced C3aR phosphorylation [15]. Our
previous studies in a transfected mast cell line, RBL-2H3 indicated
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the roles of other GRKs on the regulation of receptor function in
mast cells remain unknown.
In the present study, we utilized lentivirus shRNA to
knockdown the expression of GRK2, GRK3, GRK5 and GRK6
in human mast cells (HMC-1 and LAD2) that endogenously
express functional C3aR. Using this system, we report unexpected
findings regarding the roles of GRKs on signaling and mediator
release in mast cells via both receptor desensitization-dependent
and independent pathways.
Results
Stable knockdown of GRK2, GRK3, GRK5 and GRK6
expression in the human mast cell line HMC-1 cells
To determine the roles of GRKs on the regulation of C3aR
signaling in human mast cells, we used the Mission shRNA
lentiviral system to stably knockdown the expression of GRK2,
GRK3, GRK5 or GRK6 in a human mast cell line, HMC-1 cells.
Cells were separately transduced with 5 different shRNA
constructs targeting different regions of each GRK, and the
construct that gave the most efficient knockdown was selected for
further study. For control, we used a scrambled shRNA construct
purchased from Sigma. Although all 5 constructs reduced the
expression of each GRK to variable levels, TRCN0000230149 for
GRK2, TRCN0000159482 for GRK3, TRCN0000000842 for
GRK5 and TRCN0000001368 for GRK6 were the most efficient
in knocking down GRKs in HMC-1 cells. These constructs were
therefore used for all subsequent studies in HMC-1 and LAD2
mast cells. Using real time quantitative PCR we found that the
mRNA levels of GRK2 and GRK5 were reduced by .90% in
HMC-1 cells (Fig. 1A and 1C). However, GRK3 and GRK6
mRNA levels were reduced by .80% (Fig. 1B and 1D). Western
blot data confirmed almost complete knockdown of GRK2
(Fig. 1E) and GRK5/GRK6 (Fig. 1F). We were not able to detect
GRK3 expression with available antibodies.
GRK2 and GRK3 cause C3aR desensitization in HMC-1
cells but GRK5 and GRK6 do not
Intracellular Ca
2+ mobilization provides a rapid, sensitive and
real-time assay to measure desensitization [16]. We have
previously shown that GPCRs that undergo desensitization
respond to agonist with an initial Ca
2+ spike, which decays rapidly
and reaches baseline within ,3 min [16]. By contrast, phosphor-
ylation-deficient receptors respond to agonist for a similar initial
Ca
2+ spike, which is followed by a sustained response that remains
elevated for an extended period of time. We therefore used Ca
2+
mobilization as an assay to determine the effect of GRK2, GRK3,
GRK5, GRK6 silencing on C3aR desensitization. C3a caused a
transient Ca
2+ mobilization in shRNA control cells (Fig. 2). In
GRK2 or GRK3 knockdown (KD) cells the initial Ca
2+ response
to C3a (100 nM) was similar to shRNA control cells. However, the
response remained elevated for longer time period (Fig. 2; A–C).
By contrast, knockdown of GRK5 or GRK6 had no effect on the
magnitude or the time course of C3a -induced Ca
2+ response
(Fig. 2; D–F). To rule out the possibility that GRK5 and GRK6
could modulate Ca
2+ response to C3a at lower concentrations, we
determined the effects of silencing these GRKs on responses to
Figure 1. Stable knockdown of GRK2, GRK3, GRK5 and GRK6 in human mast cells. HMC-1 cells were stably transduced with scrambled
shRNA control lentivirus (Control) or shRNA lentivirus targeted against GRK2, GRK3, GRK5 and GRK6. (A–D) Quantitative PCR was performed to assess
GRK2, GRK3, GRK5 and GRK6 mRNA levels in shRNA control and GRK knockdown (KD) cells. Results are expressed as a ratio of GRK to GAPDH mRNA
levels. Data represent the mean 6 SEM from three independent experiments. Statistical significance was determined by unpaired two-tailed t test.
***, p,0.001. Representative immunoblots of HMC-1 cells with knockdown of (E) GRK2 and (F) GRK5/GRK6 are shown.
doi:10.1371/journal.pone.0022559.g001
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GRKs had no effect on Ca
2+ responses to C3a even at very low
concentrations.
GPCRs that undergo desensitization display reduced respon-
siveness to a second stimulation with the same agonist [16]. To test
further the effects of GRKs on desensitization, shRNA control or
GRK KD cells were exposed to C3a and washed 3 times before
re-exposure to the same concentration of C3a. shRNA control
cells displayed ,88% reduction in the calcium peak to the second
stimulation (Fig. 4A and 4F). By contrast GRK2 and GRK3 KD
cells showed ,45% and ,40% reduction in the calcium peak to
the second stimulation, respectively (Fig. 4; B, C and F). However,
Ca
2+ response to C3a in GRK5 and GRK6 KD cells was very
similar to that seen in shRNA control cells (Fig. 4; A, D, E and F).
These data demonstrate that while GRK2 and GRK3 participate
in C3aR desensitization in HMC-1 cells, GRK5 and GRK6 do
not.
Agonist-induced C3aR internalization does not require
GRK2, GRK3, GRK5 or GRK6
Receptor internalization is an important mechanism that
regulates GPCR signaling. In transfected RBL-2H3 cells, ,70%
of the cell surface receptors undergo internalization following 1
min stimulation with C3a [17]. Furthermore, C3a-induced
internalization is blocked by ,50% in cells expressing a complete
phosphorylation-deficient C3aR mutant [17]. This suggests that
phosphorylation of C3aR, at least in part, contributes to receptor
internalization. Before conducting studies on the role of GRKs on
C3aR internalization we performed flow cytometry analysis to
determine the impact of GRK knockdown on the cell surface
C3aR expression. As shown in Fig. 5A, there was no difference on
cell surface expression of C3aR in GRK2, GRK3, GRK5 or
GRK6 KD cells when compared to shRNA control cells. To
determine the role of GRKs on agonist-induced C3aR internal-
ization, we exposed shRNA control or GRK KD cells with C3a
(100 nM) for 1 min and 5 min and determined the extent of cell
surface C3aR expression by flow cytometry. Although C3a caused
a substantial loss of cell surface receptors in shRNA control cells
(,70%), there was no significant difference in the extent of
receptor internalization in GRK2, GRK3, GRK5 or GRK6 KD
HMC-1 cells (Fig. 5; B–G). These findings suggest that either
GRKs are not involved in agonist-induced C3aR internalization
or that multiple GRKs contribute to receptor internalization and
loss of one is compensated for by the presence of others.
C3a-induced ERK1/2 phosphorylation is modulated by
GRK2, GRK3, GRK5 and GRK6
C3a causes transient ERK1/2 phosphorylation in HMC-1 cells
[18]. We therefore sought to determine the effects of silencing the
expression of GRKs on ERK1/2 phosphorylation in HMC-1 cells.
Consistent with our previous studies, we found that C3a causes a
transient ERK1/2 phosphorylation that peaked at 1 min and
Figure 2. Effects of GRK2/3 and GRK5/GRK6 knockdown on C3a-induced Ca
2+ mobilization in human mast cells. GRK knockdown (KD) and
shRNA control HMC-1 cells were loaded with Indo-1 (1 mM) and Ca
2+ mobilization in response to C3a (100 nM) was performed as described in the
materials and methods. (A) and (B) show Ca
2+ responses in GRK2 and GRK3 KD cells. (C) shows peak Ca
2+ mobilization at 150–200 sec after
stimulation. (D) and (E) show Ca
2+ responses in GRK5 and GRK6 KD cells. (F) shows peak Ca
2+ mobilization between 150 and 200 sec after
stimulation. For experiments in (A), (B), (D) and (E), representative traces from three independent experiments are shown. For (C) and (F) data
represent the mean 6 SEM from three independent experiments. Statistical significance was determined by unpaired two-tailed t test. *, p,0.05.
doi:10.1371/journal.pone.0022559.g002
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silencing GRK2 and GRK3 expression enhanced C3a-induced
ERK1/2 phosphorylation at 1, 5 and 10 min. By contrast, GRK5
or GRK6 knockdown had no effect on ERK1/2 phosphorylation
at 1 min but rendered the cells responsive to C3a for enhanced
ERK1/2 phosphorylation at later time points (5–10 min) (Fig. 6;
C and D). To determine the specificity of GRKs for ERK1/2
phosphorylation, we tested the effect of PMA, which bypasses
C3aR and activates protein kinase C directly. We found that
although PMA (10 nM, at 5 min and 10 min) caused robust
ERK1/2 phosphorylation, this response was not significantly
altered in GRK5 and GRK6 KD cells (Fig. 7; A and B).
Distinct roles of GRK2/3 and GRK5/6 on C3a-induced
mast cell degranulation
Our previous studies in transfected RBL-2H3 cells indicated
that GRK2 mediates desensitization of C3aR and inhibits C3a-
induced mast cell degranulation [7]. Using shRNA-mediated
knockdown of GRKs, we sought to determine the roles of
individual GRKs on C3a-induced mast cell degranulation.
Because HMC-1 is an immature mast cell line that does not
degranulate, we utilized LAD2 mast cells, which endogenously
expresses C3aR and responds to C3a for robust degranulation [6].
As GRK2 and GRK3 are involved in C3aR desensitization in
HMC-1 cells (Fig. 2 and Fig. 4), we initially focused our studies on
these GRKs. We found that although GRK2 mRNA could be
reduced by ,80% (Fig 8A), GRK3 knockdown was less efficient
(,65%) in LAD2 cells (Fig. 8B). Silencing GRK2 or GRK3
resulted in significant enhancement of C3a-induced mast cell
degranulation (Fig. 8; C and D). Compound 48/80 induces
degranulation in human mast cells via the activation GPCRs,
MrgX1 and MrgX2 [19,20]. To determine the specificity of
GRK2 for the regulation of C3a-induced response, we tested the
ability of different concentrations of compound 48/80 to induce
degranulation in shRNA control and GRK2 KD cells. As shown
in Fig. 8E, silencing of GRK2 had no effect on compound 48/80-
induced degranulation.
Because GRK5 or GRK6 KD had no effect on C3aR
desensitization in HMC-1 cells (Fig. 2, 3, 4), we expected that
reduced expression of these GRKs will have little or no impact on
C3a-induced mast cell degranulation. To test this possibility, we
knocked down the expression of GRK5 and GRK6 in LAD2 mast
cells. As for HMC-1 cells (Fig. 1), lentiviral shRNA was efficient in
reducing mRNA for these GRKs by $75% (Fig. 9; A and B).
Unexpectedly, absence of these GRKs caused substantial inhibi-
tion of C3a-induced mast cell degranulation (Fig. 9; C and D). To
Figure 3. Silencing the expression of GRK5 or GRK6 does not modulate Ca
2+ mobilization to low concentrations of C3a. (A) shRNA control,
(B) GRK5 KD and (C) GRK6 KD HMC-1 cells were loaded with Indo-1 (1 mM), sequentially exposed to C3a 0.01 nM and 0.1 nM C3a and intracellular Ca
2+
mobilization was determined. Traces for three representative experiments are shown. For (D), peak Ca
2+ response to C3a in shRNA control, GRK5 and
GRK6 KD cells are shown. Data are the mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0022559.g003
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we tested the effect of cortistatin (CST), which activates mast cells
via MrgX2 [20,21]. As for C3a, GRK5 KD significantly reduced
CST-induced mast cell degranulation (Fig. 9E).
Discussion
GRKs are well known for their roles in GPCR desensitization
and internalization [8,9]. They also promote G protein-indepen-
dent b-arrestin-mediated downstream signaling pathways for
ERK1/2 phosphorylation [10,11,14]. Most previous studies on
GPCR regulation by GRKs have been performed with siRNA-
mediated GRK knockdown in HEK293 cells [10,11,14]. While
tremendous efforts have been devoted towards understanding the
mechanisms involved in the regulation of high affinity IgE receptor
(FceRI) almost nothing is known regarding the regulation of
GPCR signaling in mast cells. For the present study, we utilized
lentivirus shRNA to stably knockdown the expression of GRK2,
GRK3, GRK5 and GRK6 in human mast cell lines, HMC-1 and
LAD2 that endogenously express C3aR. Using this approach, we
have shown that GRK2 and GRK3 cause C3aR desensitization
but not receptor internalization. Furthermore, we provide the first
demonstration that while GRK5 and GRK6 do not cause C3aR
desensitization, they promote C3a-induced mast cell degranula-
tion but inhibit C3a-induced ERK1/2 phosphorylation.
All known GRKs (60–80 kDa) possess a similar structural
organization consisting of an amino terminal domain (185 amino
acids), a catalytic domain (270 amino acids) and a carboxyl
terminal domain (105 to 230 amino acids). There are, however,
important differences in the mechanism via which GRK2/GRK3
and GRK5/GRK6 are localized to the proximity of the receptor
to induce receptor phosphorylation [8,22]. GRK2 and GRK3 are
found primarily in the cytoplasm and undergo translocation to the
plasma membrane upon G protein activation via their interaction
with Gbc subunit and membrane phospholipids. By contrast,
GRK5 and GRK6 do not associate with Gbc but interact with
phospholipids or require lipid modification for their association
with receptors. We have previously shown that C3a caused
enhanced degranulation in RBL-2H3 cells expressing a phosphor-
ylation-deficient C3aR when compared to wild type-C3aR [7].
We also showed that overexpression of GRK2 enhances C3aR
phosphorylation to attenuate C3a-induced degranulation [7].
These findings indicated that agonist-induced C3aR phosphory-
lation by GRK2 promotes C3aR desensitization.
In the present study, we demonstrated that GRK2, GRK3,
GRK5 and GRK6 are expressed in two human mast cell lines,
HMC-1 and LAD2. Using shRNA-mediated knockdown of
GRKs, we confirmed our previous finding regarding the role of
GRK2 on agonist-induced C3aR desensitization in mast cells. In
addition, we made the novel observation that GRK3 participates
in C3aR desensitization in human mast cells. Thus, silencing the
expression of GRK2 or GRK3 resulted in more sustained Ca
2+
mobilization, greater degranulation and enhanced ERK1/2
Figure 4. Silencing GRK2 and GRK3 attenuate C3aR desensitization but GRK5 and GRK6 do not. (A) shRNA control, (B) GRK2, (C) GRK3,
(D) GRK5 and (E) GRK6 KD cells were loaded with Indo-1 (1 mM), stimulated with C3a (100 nM) for 5 min and intracellular Ca
2+ mobilization was
determined (black solid lines). The cells were washed three times with ice-cold buffer, resuspended in warm buffer and exposed to a second
stimulation of C3a (100 nM) and intracellular Ca
2+ mobilization was again determined (red broken lines). (F) Desensitization was expressed as the
percentage decrease in Ca
2+ response following second stimulation relative to the initial response. Data represent the mean 6 SEM from three
independent experiments. Statistical significance was determined by unpaired two-tailed t test. **, p,0.01 and ***, p,0.001.
doi:10.1371/journal.pone.0022559.g004
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carboxyl terminal tail of C3aR possesses nine potential phosphor-
ylation sites and both GRK2 and GRK3 promote agonist-induced
C3aR phosphorylation [7,15]. These findings suggest that in
agonist-stimulated mast cells GRK2 and GRK3 may phosphor-
ylate C3aR at the same or distinct sites to promote receptor
desensitization.
Previous studies showed that GRK5 and GRK6 promote
agonist-induced C3aR phosphorylation in transfected COS cells
[15] but the consequence of this phosphorylation remained
unknown. An interesting and novel finding of the present study
was that silencing GRK5/GRK6 had no effect on the Ca
2+
response but caused substantial inhibition of C3a-induced mast
cell degranulation. This suggests that GRK5 and GRK6 provide
stimulatory signals for mast cell degranulation. It is noteworthy
that GRK5 phosphorylates b-arrestin-1 [23]. Furthermore, we
have recently shown that b-arrestin-1 is required for C3a-induced
mast cell degranulation [24]. Previous studies demonstrated that
b-arrestin forms a complex with Ral-GDP dissociation stimulator
(Ral-GDS) in the cytoplasm of human neutrophils and that
activation of fMLP receptor results in the translocation of this
complex to the plasma membrane, resulting in the activation of
Ral [25]. Phospholipase D (PLD) is an important enzyme that
promotes mast cell degranulation [26,27,28,29]. Furthermore, the
activity of PLD is regulated by Ral [30,31]. We have shown that
cortistatin, which activates mast cells via MrgX2, also requires the
presence of GRK5 for mast cell degranulation. These findings
raise the interesting possibility that in response to GPCR
activation, GRK5/GRK6-mediated phosphorylation of b-ar-
restin-1 recruits Ral-GDS-b-arrestin-1 complex to the plasma
membrane, resulting in Ral/PLD activation to promote mast cell
degranulation. Whether this or other GRK5/GRK6-mediated
signaling pathway promotes mast cell degranulation remains to be
determined.
It is generally accepted that GRK5 and GRK6 promote
GPCR-mediated mitogen-activated protein kinase signaling path-
Figure 5. Effects of GRK2/3 and GRK5/6 knockdown on cell surface C3aR expression and agonist-induced receptor internalization.
(A) Control shRNA, GRK2, GRK3, GRK5, and GRK6 KD cells were incubated with a mouse anti-C3aR antibody or an isotype control antibody followed
by PE-labeled donkey anti-mouse IgG antibody and analyzed by flow cytometry. Cell surface C3aR in each GRK KD cells is shown as a percent of
receptor expression in shRNA control cells. (B) shRNA control and cells with knockdown of each GRKs were exposed to buffer or C3a for 1 min or
5 min and cell surface C3aR expression was determined by flow cytometry. Internalization is expressed as percent loss in receptor expression
following exposure to C3a. Data represent the mean 6 SEM from three independent experiments. (C–G) Representative histogram plots from an
internalization experiment following 5 min exposure to buffer (blue line) or C3a (red line) in shRNA control or GRK KD cells are shown.
doi:10.1371/journal.pone.0022559.g005
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agonist-induced ERK1/2 phosphorylation [10,11]. A surprising
observation of the present study was that silencing the expression
of either GRK5 or GRK6 resulted in enhanced ERK1/2
phosphorylation in response to C3a. The possibility that this
enhanced response reflects attenuated C3aR desensitization is
unlikely because reduced expression of these GRKs had no effect
on C3aR desensitization or internalization. These findings suggest
that GRK2/GRK3 and GRK5/GRK6 inhibit C3a-induced
ERK1/2 phosphorylation via distinct pathways; one involving
receptor desensitization and the other independent of receptor
desensitization.
The mechanism by which GRK5/GRK6 inhibit C3a-induced
ERK1/2 phosphorylation is not known. Similar to our finding,
Barthet et al., [23] recently showed that GRK5 inhibits 5-HT4
receptor-mediated ERK1/2 phosphorylation. They also demon-
strated that GRK5, but not GRK2, phosphorylates b-arrestin-1 (at
Ser
412) and that this phosphorylation is required for the inhibition
of ERK1/2 activity. We have recently shown that silencing the
expression of b-arrestin-1 enhances C3a-induced ERK1/2
phosphorylation via a receptor desensitization-independent path-
way [24]. This raises the interesting possibility that, as for 5-HT4
receptor, agonist-induced C3aR phosphorylation by GRK5/6
recruits b-arrestin-1 to inhibit C3a-induced ERK1/2 phosphor-
ylation. Tipping et al., [32] recently showed that the single b-
arrestin present in Drosophila, Kurtz (Krz) directly binds to and
sequesters an inactive form of ERK, thus preventing its activation
by the upstream kinase, MEK. It is therefore possible that C3a
induces b-arrestin-1 phosphorylation via GRK5/GRK6 to
promote a complex formation between ERK and b-arrestin-1,
leading to the inhibition of ERK1/2 activity. Thus, silencing the
expression of GRK5/GRK6 or b-arrestin-1 removes this
inhibitory constraint to enhance ERK1/2 phosphorylation.
Whether this or other mechanisms participate in the regulation
of ERK1/2 activity by GRK5/GRK6 in C3a-activated mast cells
remains to be determined.
In summary, the present study demonstrates that GRK2 and
GRK3 participate in C3aR desensitization in human mast cells. It
also provides the novel finding that GRK5 and GRK6 promote
C3a-induced mast cell degranulation but inhibit ERK1/2
phosphorylation via mechanisms that are independent of receptor
desensitization.
Materials and Methods
Materials
Mission shRNA bacterial glycerol stocks for GRK subtypes
were purchased from Sigma Life Sciences (St. Louis, MO). Indo-1
AM was from Molecular Probes (Eugene, OR). All tissue culture
reagents were purchased from Invitrogen (Gaithersburg, MD).
Anti-GRK 2/3 and anti-GRK5/6 was obtained from Millipore
(Billerica, MA). Anti-human C3aR was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Phycoerythrin (PE)-labeled
donkey anti-mouse IgG was purchased from eBioscience (San
Diego, CA). All recombinant human cytokines were purchased
from Peprotech (Rocky Hill, NJ). Rabbit anti-ERK1/2 and anti-
Figure 6. Silencing the expression of GRK2/3 and GRK5/6 enhance C3a-induced ERK1/2 phosphorylation. shRNA control, GRK2, GRK3,
GRK5, or GRK6 KD HMC-1 cells were washed with serum-free medium and exposed to C3a (100 nM) for 1, 5 and 10 min. Cell lysates were separated
on SDS-PAGE and blots were probed with anti-phospho-ERK1/2 antibody. The blots were then stripped and reprobed with anti-ERK1/2 antibody
followed by anti-rabbit IgG-HRP. Immunoreactive band were visualized by SuperSignal West Femto maximum sensitivity substrate. (A, C)
Representative immunoblots from three similar experiments are shown. (B, D) ERK1/2 phosphorylation was quantified from 3 experiments using
Image J software. Data represent the mean 6 SEM from three independent experiments. Statistical significance was determined by unpaired two-
tailed t test. *, p,0.05; **, p,0.01 and ***, p,0.001.
doi:10.1371/journal.pone.0022559.g006
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(Beverly, MA). LightCycler FastStart RNA Master SYBR Green I
was obtained from Roche (Indianapolis, IN). SuperSignalH West
Femto Maximum Sensitivity Substrate and HRP-labeled goat
anti-rabbit IgG were from Thermo Scientific (Rockford, IL).
Purified C3a and Phorbol-12 myristate 13-acetate (PMA) were
obtained from Advanced Research Technologies (San Diego, CA)
and Calbiochem, (Germany), respectively.
Mast cell culture
HMC-1 cells were cultured in Iscove’s modified Dulbecoo’s
medium (IMDM) supplemented with 10% FCS, glutamine
(2 mM), penicillin (100 IU/mL) and streptomycin (100 mg/mL)
[33]. LAD2 cells were maintained in complete StemPro-34
medium supplemented with 100 ng/mL rhSCF [34].
Lentivirus and stable transduction of shRNAs in mast cells
Lentivirus generation was performed according to the manu-
facture’s manual (Sigma). Cell transduction was conducted by
mixing 1.5 ml of virus with 3.5 ml of HMC-1 or LAD2 cell
(5610
6 cells). Eight hours after transduction, the medium was
changed and cells were replenished with fresh medium. After a
recovery period of 24 h, puromycin (2 mg/ml) was added to select
cells with stable virus integration into the genome. Cells were
analyzed for GRK knockdown after one week of antibiotic
selection.
Real-Time PCR
Total RNA was extracted from 1610
6 of cells using TRIZOL,
treated with DNase I and purified with RNeasy mini Kit according
to the manufacture’s instruction. Real time PCR was performed
with LightCycler FastStart RNA Master SYBR Green I (Roche
Applied Science) on a Roche LightCycler2.0 instrument. The
primers used for real time PCR were: hGAPDH Forward, 59-
GAGTCCACTGGCGTCTTCA-39 and hGAPDH Reverse, 59-
GGGGTGCTAAGCAGTTGGT -39 were used for GAPDH.
hGRK2 Forward, 59-ACT TCAGCGTGCATCGCAT-39 and
hGRK2 Reverse, 59- GCTTTTTGTCCAGGCACTTCAT-39
were used for GRK2. hGRK3 Forward, 59-AGCTGTACCT-
CAGGTGAAGTT-39 and hGRK3 Reverse, 59-AGCTTGCTTT-
GAGAAAGGATGT-39 were used for GRK3. hGRK5 Forward,
59-GACCACACAGACGACGACTTC-39 and hGRK5 Reverse,
59-CGTTCAGCTCCTTAAAGCATTC-39 were used for GRK5.
hGRK6 Forward, 59-TAGCGAACACGGTGCTACTC-39 and
hGRK6 Reverse, 59-GCTGATGTGAGGGAACTGGA-39 were
used for GRK6. The amplification conditions were as follows;,
Reverse transcription at 55uC for 10 min. Denaturation at 95uC for
30 s, 40 cycles at 95uC for 10 s, 66uC (69uC for GRK6) for 10 s,
and 72uC for 20 s. Melting curve: conditions were; 95uC, 65uC for
15 s, and 95uC (slope 0.1uC/s). Analysis was performed according
to DDCt (delta delta Ct) method. Results are expressed as a ratio of
GRK to GAPDH.
C3a Receptor desensitization assay
Receptor desensitization assay based on Ca
2+ mobilization was
determined as described previously [35]. Briefly, HMC-1 cells
(1610
6) were washed twice with HEPES buffer (119 mM NaCl,
5 mM KCl, 25 mM HEPES, 5.6 mM Glucose, 0.4 mM MgCl2,
1 mM CaCl2) containing 1 mg/ml BSA and incubated with 1 mM
of Indo-1 for 30 min in dark. Cells were then washed and
resuspended in 1.5 ml of the same buffer. The cells were
stimulated with 100 nM C3a for 5 min and mobilization of
intracellular Ca
2+ was monitored with a Hitachi F-2500
fluorospectrophotometer. For desensitization assays, cells were
removed from the cuvette, washed three times in cold buffer,
resuspended in warm buffer and Ca
2+ mobilization to a
subsequent exposure of C3a (100 nM) was determined. Desensi-
tization was expressed as percentage decrease in calcium response
following second stimulation relative to the first one.
Receptor internalization assay based on flow cytometry
Cells were washed and resuspended in fresh medium at a
concentration of 0.5610
6/ml and stimulated with C3a (100 nM)
for 1 min or 5 min at 37uC. Cells were washed twice and
resuspended in 48 ml of ice-cold FACS buffer (PBS containing 2%
FBS). C3aR antibody (2 mL) or Isotype control was added and the
cells were incubated on ice for 1 h. After washing twice with cold
FACS buffer, cells were resuspended in 48.5 ml of ice-cold FACS
buffer. PE-labeled donkey anti-mouse antibody (1.5 mL) was
added and the cells were incubated on ice for 1 h. Cells were
washed twice and fixed in 300 ml of 2% formaldehyde solution.
The samples were acquired and analyzed using FACS Calibur
flow cytometer (BD Biosciences).
ERK1/2 Phosphorylation
shRNA control and GRK knockdown HMC-1 cells were
washed twice and resuspended in serum-free IMDM at a
concentration of 1610
6/ml. Cells were stimulated with C3a
(100 nM) or PMA (10 nM) for different time points. Three-fold
volume of ice-cold PBS containing 1 mM sodium orthovanadate
Figure 7. GRKs do not modulate PMA-induced ERK1/2 phos-
phorylation. shRNA control, GRK5, or GRK6 KD HMC-1 cells were
washed with serum-free medium and exposed to phorol-myristate
acetate (PMA, 10 nM) for 0, 5 and 10 min. Cell lysates were separated
on SDS-PAGE and blots were probed with anti-phospho-ERK1/2
antibody. The blots were then stripped and reprobed with anti-ERK1/
2 antibody followed by anti-rabbit IgG-HRP. Immunoreactive band were
visualized by SuperSignal West Femto maximum sensitivity substrate.
(A) Representative immunoblots from three similar experiments are
shown. (B) ERK1/2 phosphorylation from three experiments was
quantified using Image J software.
doi:10.1371/journal.pone.0022559.g007
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22559Figure 8. Silencing GRK2 and GRK3 expression enhances C3a-induced mast cell degranulation. LAD2 cells were stably transduced with
control shRNA or shRNA lentivirus targeted against GRK2 or GRK3. (A, B) Quantitative PCR was performed to assess the GRK2 and GRK3 knockdown
and results are expressed as a ratio of GRK2 or GRK3 to GAPDH mRNA levels. (C, D) Cells were stimulated with different concentrations of C3a (0.1, 1,
10, and 100 nM) and percent degranulation (b-hexosaminidase release) was determined. (E): Control and GRK2 KD cells were exposed to different
concentrations of compound 48/80 and percent degranulation was determined. C3a (1 nM) was used as control. Data represent the mean 6 SEM
from three independent experiments. Statistical significance was determined by unpaired two-tailed t test. *, p,0.05; **, p,0.01; and ***, p,0.001.
doi:10.1371/journal.pone.0022559.g008
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22559Figure 9. Silencing GRK5 and GRK6 expression inhibits C3a-induced mast cell degranulation. LAD2 cells were stably transduced with
control shRNA or shRNA lentivirus targeted against GRK5 or GRK6. (A, B) Quantitative PCR was performed to assess the GRK5 and GRK6 knockdown
and results are expressed as a ratio of GRK5 or GRK6 to GAPDH mRNA levels. (C, D) Cells were stimulated with different concentrations of C3a (0.1, 1,
10, and 100 nM) and percent degranulation (b-hexosaminidase release) was determined. (E): shRNA control or GRK5 KD cells were exposed to
cortistatin (CST; 1 nM and 10 nM) and percent degranulation was determined. Data represent the mean 6 SEM from three independent experiments.
Statistical significance was determined by unpaired two-tailed t test. *, p,0.05; **, p,0.01; and ***, p,0.001.
doi:10.1371/journal.pone.0022559.g009
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RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% Sodium-
deoxycholate, 0.10% SDS, 50 mM Tris (pH 8.0), 5 mM EDTA,
10 mM NaF, 10 mM Na-pyrophosphate and protease inhibitor
cocktail) and subsequently analyzed by Western blot using rabbit
polyclonal antibodies for phospho-p44/42 MAPK (pERK1/2)
and p44/42 MAPK (ERK1/2).
Degranulation Assay
LAD2 cells (1.0610
4) were seeded into 96-well plates in a total
volume of 50 ml of HEPES buffer containing 1 mg/ml BSA and
exposed to different concentrations of C3a (0.1, 1, 10 and
100 nM). For total b-hexosaminidase release, control cells were
lysed in 50 ml of 0.1% Triton X-100. Aliquots (20 ml) of
supernatants or cell lysates were incubated with 20 mlo f1m M
p-nitrophenyl-N-acetyl-b-D-glucosamine for 1.5 h at 37uC. The
reaction was stopped by adding 250 ml of a 0.1 M Na2CO3/0.1 M
NaHCO3 buffer and absorbance was measured at 405 nm [35].
Data analysis
The results are expressed as mean 6 S.E.M for the values
obtained from multiple experiments. Statistical significance was
determined by unpaired two-tailed t test. *, p,0.05; **, p,0.01;
***, p,0.001.
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